Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL440250 | 0.75 | — | — | |
| SCHEMBL278457 | 0.75 | — | — | |
| SCHEMBL10751495 | 0.74 | NOS1 (0.32) | NOS1 | |
| SCHEMBL128494 | 0.72 | — | — | |
| SCHEMBL30829069 | 0.71 | LMNA (0.33) | — | |
| SCHEMBL2853189 | 0.71 | — | — | |
| SCHEMBL1577982 | 0.71 | GRIN2D (0.31) | — | |
| SCHEMBL601253 | 0.70 | FDPS (0.33) | NOS1 | |
| SCHEMBL28346497 | 0.70 | KDM4E (0.31) | — | |
| SCHEMBL11242896 | 0.70 | KMT2A (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3912641-B1 | HYDROPHILIC DRUG-LINKER COMPOUNDS | SEAGEN INC (US) | 2024-11-06 | — | — | EP | claimed |
| US-20230132738-A1 | HYDROPHILIC ANTIBODY-DRUG CONJUGATES | SEAGEN INC (US) | 2023-05-04 | — | — | US | claimed |
| US-11510959-B2 | Hydrophilic antibody-drug conjugates | SEAGEN INC. (US) | 2022-11-29 | — | — | US | claimed |
| EP-3912641-A1 | HYDROPHILIC DRUG-LINKER COMPOUNDS | Seagen Inc. (US) | 2021-11-24 | — | — | EP | claimed |
| US-20210283210-A1 | HYDROPHILIC ANTIBODY-DRUG CONJUGATES | SEAGEN INC (US) | 2021-09-16 | — | — | US | claimed |
| EP-3107557-B1 | HYDROPHILIC ANTIBODY-DRUG CONJUGATES | SEAGEN INC (US) | 2021-06-09 | — | — | EP | claimed |
| US-10933112-B2 | Hydrophilic antibody-drug conjugates | SEAGEN INC. (US) | 2021-03-02 | — | — | US | claimed |
| US-20170216391-A1 | HYDROPHILIC ANTIBODY-DRUG CONJUGATES | SEATTLE GENETICS, INC. (US) | 2017-08-03 | — | — | US | claimed |
| EP-3107557-A1 | HYDROPHILIC ANTIBODY-DRUG CONJUGATES | Seattle Genetics, Inc. (US) | 2016-12-28 | — | — | EP | claimed |
| CN-106029083-A | Hydrophilic antibody-drug conjugates | 西雅图基因公司 | 2016-10-12 | — | — | CN | claimed |
| WO-2015123679-A1 | HYDROPHILIC ANTIBODY-DRUG CONJUGATES | SEATTLE GENETICS, INC. (US) | 2015-08-20 | — | — | WO | claimed |
| US-12257281-B2 | Hydrophilic antibody-drug conjugates | SEAGEN INC. (US) | 2025-03-25 | — | — | US | disclosed |
| EP-3912641-B1 | HYDROPHILIC DRUG-LINKER COMPOUNDS | SEAGEN INC (US) | 2024-11-06 | — | — | EP | disclosed |
| US-20240115648-A1 | HYDROPHILIC ANTIBODY-DRUG CONJUGATES | SEAGEN INC (US) | 2024-04-11 | — | — | US | disclosed |
| US-20230132738-A1 | HYDROPHILIC ANTIBODY-DRUG CONJUGATES | SEAGEN INC (US) | 2023-05-04 | — | — | US | disclosed |
| EP-1191106-B1 | Process for the fermentative preparation of non-proteinogenic L-amino acids | CONSORTIUM ELEKTROCHEM IND (DE) | 2004-04-28 | — | — | EP | disclosed |
| US-6579705-B2 | Generating preferential amino acid sequences; obtain adjusted amino acid, incubate with enzyme, recover amino acid | CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE GMBH (DE) | 2003-06-17 | — | — | US | disclosed |
| EP-1247869-A1 | Process for the production of non-proteinogenic amino acids | Consortium für elektrochemische Industrie GmbH (DE) | 2002-10-09 | — | — | EP | disclosed |
| US-20020039767-A1 | Process for producing non-proteinogenic L-amino acids by fermentation | CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE GMBH | 2002-04-04 | — | — | US | disclosed |
| EP-1191106-A1 | Verfahren zur fermentativen Herstellung von nicht-proteinogenen L-Aminosäuren | Consortium für elektrochemische Industrie GmbH (DE) | 2002-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020039767-A1 | Process for producing non-proteinogenic L-amino acids by fermentation | CBS, BCAT2, BCAT1 | NOS1 142/4885 |
| US-20210283210-A1 | HYDROPHILIC ANTIBODY-DRUG CONJUGATES | CD44, FCGR1A, FCGR2A | NOS1 4418/4885 |
| US-11510959-B2 | Hydrophilic antibody-drug conjugates | CD44, FCGR1A, FCGR2A | NOS1 4418/4885 |
| US-12257281-B2 | Hydrophilic antibody-drug conjugates | CD44, FCGR1A, FCGR2A | NOS1 4418/4885 |
| US-20240115648-A1 | HYDROPHILIC ANTIBODY-DRUG CONJUGATES | CD44, FCGR1A, FCGR2A | NOS1 4418/4885 |
| US-20170216391-A1 | HYDROPHILIC ANTIBODY-DRUG CONJUGATES | CD44, FCGR1A, FCGR2A | NOS1 4418/4885 |
| US-10933112-B2 | Hydrophilic antibody-drug conjugates | CD44, FCGR1A, FCGR2A | NOS1 4418/4885 |
| US-20230132738-A1 | HYDROPHILIC ANTIBODY-DRUG CONJUGATES | CD44, FCGR1A, FCGR2A | NOS1 4418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.